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Abstract
Neuroinflammation is a common pathological event observed in many different brain diseases, frequently
associated with blood brain barrier (BBB) dysfunction and followed by cerebral edema. Neuroinflammation is
characterized with microglia activation and astrogliosis, which is a hypertrophy of the astrocytes. Astrocytes express
aquaporin 4, the water channel protein, involved in water homeostasis and edema formation. Aside from its
function in water homeostasis, recent studies started to show possible interrelations between aquaporin 4 and
neuroinflammation. In this review the roles of aquaporin 4 in neuroinflammation associated with BBB disruption
and cerebral edema will be discussed with recent studies in the field.
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The purpose of this review is not to discuss neuroin-
flammation mechanisms or an extensive review of aqua-
porin 4 (AQP4), for there are numerous reviews
covering these two topics independently. Rather, we ad-
dress the question whether AQP4 is a common player
between edema and neuroinflammation by reviewing the
recent literature in the field. In recent years, AQP4 has
been associated with neuroinflammation in chronic and
acute brain diseases [1-12]. Since AQP4 is mostly
expressed on the astrocytes, and because neuroinflam-
mation is characterized by both phenotypic changes of
resting astrocytes to astrogliosis and microglial activa-
tion, we believe that tackling this question can lead to a
better understanding of many brain diseases.
General introduction
Aquaporin 4 - overview
Aquaporin (AQP) is a family of water channel protein ubi-
quitously expressed in various cell types and organisms
[13]. The aquaporin family exhibits a common structure
with six membrane spanning alpha helical domains, a con-
sensus motif composed of Asparagine-Proline-Alanine
(NPA) constituting part of the pore, and an approximate
molecular weight of 30 kDa [14]. AQP4 is the most abun-
dant AQP found in the primate and rodent brains, mainly
in the perivascular astrocyte endfeet [13]. AQP4 is
assembled in homo-tetramers where each individual aqua-
porin represents a water channel (Figure 1A) [15]. The as-
semblage of four molecules of AQP4 forms a central pore,
through which water, cations, and gases such as CO2 flow
[16]. Interestingly, AQP4 proteins are major constituents
of a higher structural arrangement within astrocyte end-
foot named the orthogonal arrays of particles (OAPs)
observed using electron microscopy after cryo-fracture
preparation [17] (Figure 1B). The size of the OAPs is
determined by the ratio between the two main isoforms of
AQP4: the long (AQP4-m1) and short (AQP4-m23) splice
variants (Figure 1B) [17]. The AQP4-m23 isoform stabi-
lizes the OAP structure [17,18]. The exact functional roles
of the OAPs remain unknown both in normal and patho-
logical brains. An increase in the AQP4 m1 variant dis-
rupts the structure of the OAPs [17,18], which is observed
in stroke [19,20] and parallels blood–brain barrier (BBB)
disruption. The role of AQP4 within the perivascular
space and in BBB structure is still a matter of discussion
and unresolved [21,22]. Interestingly, OAPs were pro-
posed to play a role in potassium buffering [23,24].
Strengthening this hypothesis, AQP4 found in the astro-
cyte endfeet facing cerebral blood vessels co-localized with
the potassium channel, Kir4.1 [25,26]. AQP4 knockout
mice (AQP4−/−) showed a delay in potassium reuptake
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suggesting that AQP4 has a role in potassium homeostasis
in facilitating water diffusion along the potassium gradient
during brain activity [27]. Not only involved in water
movement, AQP4 may also contribute to cell adhesion
[28] and migration [29]. These data underline the diversity
and complexity in AQP4 functions, and the subsequent
sections will show another possible function of AQP4 in
the process of neuroinflammation.
Microglia, astrocytes, and AQP4 in the context of
neuroinflammation
Neuroinflammation is largely described in the acute phase
after brain injury, along with edema, as well as in chronic
brain diseases like multiple sclerosis. The term, ‘neuroin-
flammation’, encompasses several molecular and cellular
modifications without a clear, unified definition amongst
the various brain diseases and injuries. However, it is
Figure 1 Structural organization of AQP4 in the astrocyte membrane. (A) Schematic drawing of the AQP4 homo-tetramer assembly within
the lipid membrane from a lateral view resulting in a central pore permeable to cations and gases (green arrows) [16]. Each individual aquaporin
facilitates bi-directional water movement that is dependent on the osmotic gradient (blue arrows) (modified from Badaut et al. [57]). (B) In normal
brain, association between AQP4-m1 (red circles) and AQP4-m23 (blue circles) isoforms contribute to form orthogonal array of particles (OAPs).
Higher expression of AQP4-m23 contributes to the formation of large OAPs, and should facilitate the gas, ion (green arrows), and water diffusion
(water arrows) through the astrocyte membrane. (C) In brain injury, increase of AQP4-m1 [19] should contribute to disruption of OAPs (modified
from Badaut et al. [57]). Changes in OAP size may decrease the number of central pore and possibly affect not only water movement but also
the ion and gas movements.
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important to realize that neuroinflammation is distinct
from peripheral inflammation [30-32], even if they share
some of the same molecular players, particularly due to
microglia and astrocytes, which are cells specific to the
CNS. Since the inflammatory process may differ from
organ to organ [31], Graeber and colleagues recently drew
the attention to the potential danger of using the two ter-
minologies ‘neuroinflammation’ and ‘inflammation’
interchangeably.
Although microglia is the cell type considered to be pri-
marily responsible for the innate immune response in the
CNS [33,34], it is premature to conclude that a decrease in
microglial activation is the only evidence needed for the
treatment of neuroinflammation with anti-inflammatory
drugs [30]. Activation status for both astrocytes and micro-
glia, along with secretion of cytokines and chemokines,
should be considered for neuroinflammation. Microglial ac-
tivation is characterized by morphological changes in which
the usually ramified microglia becomes round with no rami-
fications [33]. There seems to be a dual role for microglial
activation in which acute activation is beneficial [35] but a
chronic one is detrimental [33,36]. In fact, activated micro-
glia is responsible for producing pro-inflammatory cytokines
such as IL-1β, IL-6, TNFα and also anti-inflammatory cyto-
kines such as IL-4, IL-10 and TFGβ [37].
Activated astrocytes also play a key role in neuroinflam-
mation with their involvement in astrogliosis, although
whether astrogliosis is beneficial or detrimental seem to de-
pend on the situation [38], much like microglial activation.
The process of astrogliosis includes the hyptertrophy of
astrocytes with different morphological fates depending on
the severity of the injury [39]. The absence of AQP4 in
astrocytic endfeet may lead to decreased hypertrophy of
astrocytes due to decreased water entry and migration to-
ward the site of the injury [29,40]. Like microglia, activated
astrocytes contribute to the secretion of chemokines and
cytokines (see examples above), possibly involved in BBB
disruption and vasogenic edema. Interestingly, AQP4 is
upregulated in the vasogenic edema resolution phase visua-
lized by normalization of magnetic resonance (MR) signals
in several disease models [2,41]. Furthermore, AQP4 has
also been reported to be present in reactive microglia after
intranigral injection of lipopolysaccharide (LPS) in rats, al-
though the functional significance of this de novo microglial
AQP4 expression is unknown [42]. These changes in AQP4
during the inflammatory process suggest changes in water
movement related to neuroinflammation.
AQP4 and neuroinflammation in autoimmune
diseases
Experimental autoimmune encephalomyelitis (EAE) and
AQP4
Recent data in a model of experimental autoimmune en-
cephalomyelitis (EAE) in which homogenized guinea-pig
whole spinal cord was injected into rats showed upregu-
lation of AQP4 starting at 10 days until the onset and
peak of cerebellar enlargement. At these timepoints, sig-
nificantly positive correlation was observed between
AQP4 and BBB disruption in the cerebellum, associated
with a decrease of tight junction proteins such as occlu-
din [7]. This detrimental role of AQP4 in EAE is sup-
ported by a less severe clinical and tissue inflammation
score after EAE and LPS-injection in AQP4−/− mice than
WT animals [1]. This is most likely the cause of reduced
production of the pro-inflammatory cytokines, TNFα
and IL-6, observed in AQP4−/− mice astrocyte cultures
[1].
AQP4−/− mice studies have also suggested that AQP4
could be contributing to the production of CD4+ and
CD25+ T regulator cells; and lack of AQP4 may be
disrupting the immunosuppressive regulators in Parkin-
son’s disease, leading to increased microglial activation
and a worse outcome due to more dopaminergic neur-
onal loss after induction of 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine [5]. Interestingly, AQP4 expression is
present in the spleen, lymph nodes, and thymus, hinting
towards a more direct role of AQP4 in systemic immune
responses, and perhaps not just confined to neuroin-
flammation [5].
Neuromyelitis optica (NMO) and AQP4
The possible link between neuroinflammation and
AQP4 was advertised with neuromyelitis optica (NMO),
a demyelinating disease. NMO is a pathological condi-
tion characterized by abnormal signals most often
observed in the spinal cord and optic nerve, and in the
form of blindness and paralysis. Interestingly, AQP4 has
been identified as the target for NMO-IgG, a unique fea-
ture of the disease which differentiates it from multiple
sclerosis [43-45], making it a very useful differential
diagnostic tool in the clinics. More specifically, there is
plausible evidence that NMO-IgG specifically targets
AQP4 within the OAP structures, rather than free AQP4
isoforms [6,46,47]. Whether the presence of an autoanti-
body against AQP4 is the cause of the disease or a col-
lateral consequence of some secondary pathological
mechanisms still lacks an unanimous answer, but studies
performed where immunoglobulins taken from AQP4
antibody positive NMO patients were administered to
rats with EAE showed NMO pathology seen in the
clinics [48,49], suggesting that the presence of AQP4
autoantibody in patients already suffering from neuroim-
mune disease worsens the condition and leads to the
NMO pathology observed. Interestingly, several clinical
observations have been reported in which patients with
myasthenia gravis (MG) also suffer from auto-AQP4-
antibody positive NMO simultaneously [50-56]. Thus
pointing out the possibility of a common autoimmune
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origin for both diseases, or the aforementioned worsen-
ing effect of the AQP4 autoantibody in patients with
pre-existing immune diseases; previously unrecognized
because of the lack of knowledge about the NMO IgG
auto-AQP4 antibody as a diagnostic tool for NMO. This
link could point to the involvement of AQP4 in the per-
ipheral immune system as well.
In summary, these recent data from NMO and AQP4−/−
mice models are encouraging to propose that AQP4 is a
player in inflammation and neuroinflammation. But con-
sidering AQP4 properties as a water channel, its function
in these processes are still unclear.
Neuroinflammation and edema in brain injury:
astrocyte AQP4
BBB breakdown and vasogenic edema
AQP4 is one of the key players in edema formation and
resolution [57,58] and increase in its expression is
observed in reactive astrocytes after injury. Edema is fre-
quently observed in brain injuries and is associated with
BBB disruption [57,59]. Compromised BBB integrity
leads to plasma protein leakage and extravascular fluid
accumulation [57]. The breakdown of the BBB is a com-
plex process partially caused by the activation of matrix
metalloproteinases (MMPs), which is part of the
neuroinflammatory response [60-62]. Pro-inflammatory
cytokines such as IL-1β and TNFα has been shown to
produce MMP-9 and MMP-3 in cultured astrocytes and
microglia (reviewed in [62]). MMP-9 aggravates vaso-
genic edema development by degrading the basal lamina
located between the astrocytic endfeet and endothelia
[62]. Of particular interest is the link of MMP with
AQP4; MMP-2 and MMP-9 are known to degrade agrin
and MMP-3 degrades dystroglycan [63], two proteins
that have a critical role in the maintenance of the OAP
[64-67]. So, when MMP are upregulated after a neuroin-
flammatory response, more AQP4-OAPs will be disorga-
nized, leading to a possible disruption of the BBB and
edema. Vasogenic edema development can further dam-
age the endothelia by increased water volume and there-
fore increased hydrostatic pressure. Thus, if there is
decreased BBB disruption, there will be less pro-
inflammatory cytokines, MMPs, and edema (Figure 2).
Magnetic resonance imaging and AQP4
One useful modality in assessing injury severity and out-
come in cerebral pathological conditions both in clinics
and research is magnetic resonance imaging (MRI). Be-
cause MRI detects changes observed via the excitation
of water molecules, the presence of the water channel
Figure 2 Schematic summary of a beneficial role AQP4 upregulation plays during the edema resolution phase. The upregulation of
AQP4 causes increased water clearance from the tissue, which in turn causes decreased BBB disruption because of decreased pressure, and there
is less neutrophil infiltration and decreased pro-inflammatory cytokines. This cause decreased MMP production [62], which possibly results in less
destruction of the basal lamina and tight junctions, causes an even greater decrease of the BBB. In another pathway (dotted lines), the increased
water clearance from the tissue and extracellular space causes changes in the osmotic pressure, changing the activation state of the stretch
activated ion channels expressed in microglia [86-88], causing less microglial activation, thus causing decreased pro-inflammatory cytokine. The
resulting decrease in BBB disruption/permeability leads to decreased vasogenic edema or better edema resolution. Finally, this scheme outlines
the potential link between AQP4, edema and neuroinflammation.
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protein, AQP4 in astrocytes suggests a possible involve-
ment in MRI. Diffusion-weighted magnetic resonance
imaging (DWI) is widely used as a diagnostic tool in
clinical and research settings to assess edematous dam-
age after various brain pathologies from ischemic stroke
to various neuroinflammatory diseases [57,68-71]. The
apparent diffusion coefficient (ADC) is obtained from
DWI and is used to evaluate cerebral changes in clinical
and experimental models. A decrease in the ADC is
classically associated with a decrease in the extracellular
space during cell swelling after brain injury [70]. More
recently, ADC changes have been hypothesized to be
linked with the level of expression of AQP4. Several
experiments have shown increases in AQP4 expression
and increased ADC [71] and decreased AQP4 expression
with decreased ADC [58,72]. Of note, Tourdias et al. [2]
have recently shown in a model of focal inflammation
that AQP4 upregulation was associated with early edema
formation via increased ADC, peak BBB disruption, and
increased pro-inflammatory cytokine secretion. Diffusion
tensor imaging (DTI) takes into account the non-
uniform directionality of water flow (anisotropy) in the
brain. This anisotropy has mainly been attributed to
myelinated neuronal axons in the white matter tract, but
recent evidence has hinted towards the possible role of
astrocytes and glial scars in DTI signal changes after
traumatic brain injury [73]. In fact, increased anisotropy
was correlated with reactive astrocytes and not with
axonal changes in the perilesional cortex [73]. This idea
is supported by a study showing a correlation with
changes in DTI signals associated with hypertrophic
astrocytes and increase of AQP4 [74]. As AQP4 expres-
sion changes after brain injury in astrocytes and micro-
glia, it is rational to think that MRI may be a useful tool
to evaluate the evolution of the neuroinflammatory
process, especially in conjunction with AQP4 and
edema.
Edema resolution in inflammatory conditions and AQP4
In focal brain inflammation, AQP4 expression is upregu-
lated during the edema resolution phase at 2 to 14 days
post injury [2]. However the exact role of this increase
in AQP4 is still a matter of discussion. In brain injection
of L-α-lysophosphatidylcholine, a significant increase in
AQP4 expression was observed at the edema resolution
phase (7, 14, and 20 days post injection) compared to
the edema build-up phase (1 and 3 days post injection).
In this model, the edema resolution phase was defined
as a return to baseline for ADC values and a lower IL-1β
mRNA level, compared to the edema build-up phase [2].
Interestingly, a similar observation was made in a model
of juvenile traumatic brain injury with upregulation of
AQP4 observed during the edema resolution period
when ADC is returning to normal [41]. These data
suggest that the presence of AQP4 plays a positive role
during edema resolution by facilitating water extravasa-
tions from the brain parenchyma to liquid compart-
ments including CSF and blood vessels (Figure 2).
In stroke pathophysiology, animals with a pre-existing
inflammatory condition had aggravated stroke outcomes
as seen by more edema and BBB damage at 24 h after
injury compared to groups with no pre-existing inflam-
mation in the periphery [75]. Pre-existing systemic in-
flammation induced a surge in the levels of IL-1 in the
ischemic cerebral cortex [75]. Interestingly, increase in
IL-1α expression bordering dilated blood vessels in the
ipsilateral cortex was observed, signifying a possible dir-
ect role of pro-inflammatory cytokines on edema forma-
tion [75]. Because IL-1β has been shown to induce
AQP4 in astrocytes [76,77], and blocking either AQP4
through gene deletion [78] or IL-1β through anti-IL-1β
antibody [79] was seen to decrease edema, AQP4 may
be a possible target for systemic inflammation leading to
increased edema. In a mouse model of atherosclerosis
(APOE−/− mice under high fat diet), development of
chronic inflammation due to adhesion of a large number
of T cells and macrophages in the vasculature [80], as
well as microglial activation in the brain is observed
[81]. These mice upon aging showed BBB leakage and
higher astrogliosis associated with increased AQP4 [4].
These changes may contribute to a worse outcome in
aged atherosclerotic patients who suffer an ischemic
stroke because of higher risk of edema.
AQP4 and microglial activation after injury
There are recent interesting data concerning the rela-
tionship between AQP4 and microglial activation. A link
between neuroinflammation and AQP4 was described
using the AQP4−/− mice that are more susceptible to sei-
zures (decreased seizure latency and increased seizure
severity) compared to WT 1 month after TBI and asso-
ciated with a decrease in neuroinflammatory processes
[82]. This difference is related to the neuroinflammatory
response showing less astrogliosis and increased micro-
glial activation in AQP4−/− compared to WT mice. Min-
ocycline injection in AQP4−/− inhibited the increase in
microglia and also mitigated the severity of the post-
traumatic seizure [82]. Similar observations were reported
in a model of cryoinjury with increased microglia and
reduced astrogliosis in AQP4−/− mice compared to WT at
7 and 14 days post injury. In this model the authors
reported a decrease in the lesion volume and lower neur-
onal loss in AQP4−/− mice compared to WT at 1 day after
injury, and the opposite result at 7 and 14 days [83]. Simi-
larly, in adult rats, intravenous minocycline administration
after TBI [84] and subarachnoid hemorrhage [85] resulted
in less BBB disruption associated with decreased MMP9
and AQP4 at 1 day post injury. In our lab, we have also
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observed that treatment with small interference RNA
(siRNA) targeted against AQP4 (siAQP4) after juvenile
TBI showed a decrease in AQP4 associated with less BBB
disruption, edema, more NeuN positive cells, and better
behavior outcomes compared to the control group at
3 days post injury (unpublished data). As shown in the
adult model, we have also noticed a significant increase of
activated microglia cells and decreased astrogliosis around
the lesion at 3 days post injury in siAQP4-treated rats
compared to controls (unpublished data). All together,
these data underline that changes in AQP4 expression are
associated with changes in astrogliosis and microglia acti-
vation in acute brain injury (Figure 3). Astrogliosis may re-
quire the presence of AQP4 to facilitate the water
movement necessary for the migration [29,40] and hyper-
trophy. However, the mechanism behind the decrease of
the AQP4 and activation of microglia is less obvious and
still unknown. One possible mechanism behind the
changes observed in post-traumatic or ischemic microglia
activation and cytokine release in response to AQP4
downregulation or inhibition may be partly due to the
presence of stretch-activated Cl- channels expressed in
microglia [86,87]. Stretch-activated/swelling-activated Cl-
channels are activated by osmotic stress [88]. It has been
observed that the activation of these channels contributes
the maintenance of the non-activated (ramified) pheno-
type of microglia [86]. Because AQP4 is responsible for
water transport, inhibition of AQP4 either through genetic
deletion or siRNA will alter the osmotic stress within the
extracellular space surrounding the microglia, changing
the activation status of the swelling activated chloride
channels, resulting in microglial activation (Figures 2 and
3). Another possibility lies in the cross-talk that occurs be-
tween astrogliosis and microglial activation [34]. It is pos-
sible that the decreased extent of injury-induced reactive
astrogliosis as a result of knocking down AQP4 caused
increased microglial activity.
In summary, the presence of AQP4 seems to play a
detrimental role acutely, but at a later phase starting
from around 7 days post injury for at least 1 month,
AQP4 may play a beneficial role that seems to be
involved with inhibiting activation of microglia and pro-
moting edema resolution.
Conclusion
As reviewed, AQP4 has a key role in the edema process,
which may be followed by ADC changes in different
brain pathologies. However, whether the presence of
AQP4 is beneficial or detrimental seem to depend on
the timepoint and injury models. In vasogenic edema,
where the BBB is compromised, AQP4 seems to play a
beneficial role in eliminating accumulating water from
the extracellular space of the CNS (Figure 2). Edema is
frequently associated with neuroinflammation with acti-
vation of the microglia and astrogliosis. The upregula-
tion of AQP4 previously associated with edema recovery
may also contribute to the neuroinflammatory process
in astrogliosis and microglia inactivation. In fact, absence
or decrease of AQP4 is associated with decrease of
astrogliosis and increase of microglia activation. How-
ever, the molecular mechanisms of the water channel,
AQP4, with the inflammation process are still unknown.
But these recent data are encouraging to hypothesize
that AQP4 could be a common denominator between
Figure 3 AQP4 distribution in the astrocyte in normal cortex and after brain injury. (A) Confocal picture of AQP4 immunostaining (red,
arrow heads) in normal brain shows the presence of the water channel protein on the astrocyte endfoot (GFAP staining, green, arrow) in contact
to the blood vessels in the cortex. (B) Confocal pictures of the AQP4 immunostaining (red) on reactive astrocytes revealed with GFAP
immunolabelling (green) in the cortex after traumatic brain injury. The presence of the AQP4 staining is not only localized on the endfeet in
contact to the blood vessels but also distributed in all astrocyte processes (arrows). Scale bar 10 μm.
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edema and neuroinflammation, and underscores the im-
portance of independent investigation to understand
how AQP4 is contributing to the neuroinflammatory
and edematous process.
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